THE BEST SIDE OF "3

All enrolled people who obtained no less than a single dose of zosuquidar or placebo throughout induction have been monitored for that prevalence of adverse functions (439 individuals, 219 on zosuquidar and 210 on placebo). The most common adverse occasions have been connected to the duration of extended and substantial myelosuppression as is antic